Injections are the most common health care procedure performed in the
world and the most deadly. Each year clinicians administer 16 billion iatrogenic
injections using a pre-used syringe resulting in 1.3 million deaths, 26 million
life years lost and 32% of all new Hepatitis B cases (Hutin & Chen, 1999). Following
a global call by the World Health Organisation (WHO) in 1986 the autodestruct
syringe has since become a prerequisite device for all immunization
programmes (95%). However cost has prevented its widespread adoption in a
curative context (5%). Reaffirming absolute patient safety is illusory (Fischhof
et al, 1981). Our presentation (and exhibit) describes a two-year process to
develop an effective innovation and implementation strategy to contribute to
a global reduction in curative syringe reuse violations through design. This undertaking
involved precedent case studies, force-field analysis, and dialogues
with global networks and specialists. Our acquired knowledge base captured
Figure 1: Transforming syringe label exhibit, Design4Health 2013
the complexity of the challenge, sharpened the acuity of our strategic approach
and identified essential team competencies: high-level advocacy,
frugality, unilateral benefits (Howitt, 2012) and an acceptance for satisfice
solutions (Simon, 1959). The outcome is not a new syringe but a transformative
label that synthesizes theories of risk perception, chromism and visual design
(Fig.1).
A patented intervention that adds intrinsic value to any production syringe
thereby amplifying its impact to global patient safety: disposable, auto-destruct
or pre-filled. Marc Koska OBE Founder of the SafePoint Trust recognised
the significance of our condition-change feature, as a package sterility indicator
while transiting the supply chain and as a visual alarm indicating prior use
of medical devices to unsuspecting patients. Assisted by Marc Koska, a new
draft mandate that aims to outline future performance requirements for WHOcertified
injectable technologies now specifies our technological advance.
Project execution is now our primary objective.
world and the most deadly. Each year clinicians administer 16 billion iatrogenic
injections using a pre-used syringe resulting in 1.3 million deaths, 26 million
life years lost and 32% of all new Hepatitis B cases (Hutin & Chen, 1999). Following
a global call by the World Health Organisation (WHO) in 1986 the autodestruct
syringe has since become a prerequisite device for all immunization
programmes (95%). However cost has prevented its widespread adoption in a
curative context (5%). Reaffirming absolute patient safety is illusory (Fischhof
et al, 1981). Our presentation (and exhibit) describes a two-year process to
develop an effective innovation and implementation strategy to contribute to
a global reduction in curative syringe reuse violations through design. This undertaking
involved precedent case studies, force-field analysis, and dialogues
with global networks and specialists. Our acquired knowledge base captured
Figure 1: Transforming syringe label exhibit, Design4Health 2013
the complexity of the challenge, sharpened the acuity of our strategic approach
and identified essential team competencies: high-level advocacy,
frugality, unilateral benefits (Howitt, 2012) and an acceptance for satisfice
solutions (Simon, 1959). The outcome is not a new syringe but a transformative
label that synthesizes theories of risk perception, chromism and visual design
(Fig.1).
A patented intervention that adds intrinsic value to any production syringe
thereby amplifying its impact to global patient safety: disposable, auto-destruct
or pre-filled. Marc Koska OBE Founder of the SafePoint Trust recognised
the significance of our condition-change feature, as a package sterility indicator
while transiting the supply chain and as a visual alarm indicating prior use
of medical devices to unsuspecting patients. Assisted by Marc Koska, a new
draft mandate that aims to outline future performance requirements for WHOcertified
injectable technologies now specifies our technological advance.
Project execution is now our primary objective.
